Bolt Biotherapeutics (FRA:6LP) EBIT per Share : €-1.81 (TTM As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics EBIT per Share?

Bolt Biotherapeutics's EBIT per Share for the three months ended in Jun. 2024 was €-0.46. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €-1.81.

During the past 3 years, the average EBIT per Share Growth Rate was -9.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was -9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Bolt Biotherapeutics's EBIT per Share or its related term are showing as below:

FRA:6LP' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -31.3 Med: -9.3 Max: -3
Current: -9.3

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Bolt Biotherapeutics was -3.00% per year. The lowest was -31.30% per year. And the median was -9.30% per year.

FRA:6LP's 3-Year EBIT Growth Rate is ranked worse than
66.06% of 1255 companies
in the Biotechnology industry
Industry Median: 2.9 vs FRA:6LP: -9.30

Bolt Biotherapeutics's EBIT for the three months ended in Jun. 2024 was €-17.68 Mil.

Bolt Biotherapeutics EBIT per Share Historical Data

The historical data trend for Bolt Biotherapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics EBIT per Share Chart

Bolt Biotherapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-1.99

-1.27

-2.47

-2.28

-1.85

Bolt Biotherapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
EBIT per Share	Get a 7-Day Free Trial															-0.49	-0.45	-0.48	-0.41	-0.46

Bolt Biotherapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Bolt Biotherapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-69.872	/	37.812
=	-1.85

Bolt Biotherapeutics's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

	EBIT per Share		(Q: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-17.681	/	38.128
=	-0.46

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.81

Bolt Biotherapeutics (FRA:6LP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Bolt Biotherapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Bolt Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (FRA:6LP) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

BOLT:USA 6LP:Germany

Address

900 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.boltbio.com

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Bolt Biotherapeutics Headlines

No Headlines